Business
Basilea awarded additional CARB-X funding of USD 6 million to support the clinical development of antibiotic BAL2420
Funding is awarded following successful completion of IND-enabling studies and clinical study authorization USD 6 million in additional funding to support antibiotic BAL2420 (LptA inhibitor) first-in-human clinical study Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland, April 09, 2026 Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced toda
About this update from Basilea Pharmaceutica Ag
[{"type":"image","alt":"Basilea Pharmaceutica International Ltd, Allschwil","displaySize":"","headline":null,"caption":"Basilea Pharmaceutica International Ltd, Allschwil","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":102,"url":"https://media.zenfs.com/en/globenewswire.com/a45f97ddaed549237a3a9f58773435b7"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/KDLTjVQMNujcmBQNgU49zA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0Mw--/https://media.zenfs.com/en/globenewswire.com/a45f97ddaed549237a3a9f58773435b7","width":300,"height":102}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Funding is awarded following successful completion of IND-enabling studies and clinical study authorization ","length":107,"tagName":"p"}]},{"val":[{"type":"text","content":"USD 6 million in additional funding to support antibiotic BAL2420 (LptA inhibitor) first-in-human clinical study ","length":112,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":219,"olType":false},{"type":"text","content":"Ad hoc announcement pursuant to Art. 53 LR","length":42,"tagName":"p"},{"type":"text","content":"Allschwil, Switzerland, April 09, 2026","length":38,"tagName":"p"},{"type":"text","content":"Basilea Pharmaceutica Ltd, Allschwil (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that it was awarded an additional USD 6 million from CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator), a global non-profit partnership dedicated to supporting the early development of antibacterial products. The additional non-dilutive funding will support the first-in-human phase 1 clinical study of Basilea’s novel antibiotic BAL2420 (LptA inhibitor)1 and related activities. The phase 1 study has already been initiated, with the first subject dosed in March 2026.","length":702,"tagName":"p"},{"type":"text","content":"Dr. Marc Engelhardt, Chief Medical Officer of Basilea, said: “We are very pleased with CARB-X’s continued support, as we advance our promising first-in-class LptA inhibitor through early clinical development. BAL2420 offers a new mode of action with the potential to address significant unmet medical needs in the treatment of severe Gram-negative bacterial infections including those c...